How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about selumetinib

    Marketing authorisation indication

    2.1 Selumetinib (Koselugo, AstraZeneca) has a marketing authorisation in the UK for the 'treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1 aged 3 years and above'.

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics.

    Price

    2.3 The price for selumetinib is £4,223.59 for a 10 mg 60-capsule pack and £10,560.00 for a 25 mg 60-capsule pack (excluding VAT; company submission). The company has a commercial arrangement, which would have applied if the technology had been recommended.